Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus PENTIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus PENTIDS 250.
KLEBCIL vs PENTIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
250 mg orally every 8 hours.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic